Get the Stockscreener App
0.24
16.67%
-0.048
After Hours:
.24
Ensysce Biosciences Inc stock is traded at $0.24, with a volume of 716.60K.
It is down -16.67% in the last 24 hours and down -39.24% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.288
Open:
$0.248
24h Volume:
716.60K
Relative Volume:
0.41
Market Cap:
$2.54M
Revenue:
-
Net Income/Loss:
$-10.63M
P/E Ratio:
-0.0029
EPS:
-82.86
Net Cash Flow:
$-10.78M
1W Performance:
-18.37%
1M Performance:
-39.24%
6M Performance:
-69.63%
1Y Performance:
-82.61%
1-Day Range:
$0.2308
$0.2497
1-Week Range:
$0.2308
$0.3114
52-Week Range:
$0.2308
$2.06
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Ensysce Biosciences Inc Stock (ENSC) Latest News
Ensysce Biosciences faces Nasdaq delisting over noncompliance - Investing.com
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Ensysce Biosciences Receives Notice from Nasdaq - AccessWire
Ensysce Biosciences Receives Notice from Nasdaq - Yahoo Finance
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update - Defense World
Ensysce Biosciences Presenting at Upcoming Meetings - AccessWire
Ensysce Biosciences Presenting at Upcoming Meetings - Nasdaq
ENSC stock touches 52-week low at $0.31 amid market challenges - Investing.com Canada
ENSC stock touches 52-week low at $0.31 amid market challenges - Investing.com India
ENSC stock touches 52-week low at $0.31 amid market challenges - Investing.com UK
Ensysce Biosciences submits Phase 3 study protocol for pain treatment - Investing.com
Ensysce Biosciences submits Phase 3 study protocol for pain treatment By Investing.com - Investing.com Australia
Ensysce Biosciences Submits Phase 3 Protocol to the FDA - AccessWire
Ensysce Biosciences Submits Phase 3 Protocol to the FDA - StockTitan
Ensysce Biosciences Submits Phase 3 Protocol to the FDA - Yahoo Finance
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 - AccessWire
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 - Yahoo Finance
Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Increases By 3,885.0% - Defense World
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 - StockTitan
ENSC stock touches 52-week low at $0.34 amid market challenges - Investing.com India
ENSC stock touches 52-week low at $0.34 amid market challenges - Investing.com
Is Ensysce Biosciences Inc (ENSC) worth investing in despite its undervalued state? - US Post News
Market Insight: Ensysce Biosciences Inc (ENSC)’s Notable Drop, Closing at 0.40 - The Dwinnex
Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On? - MSN
ENSC stock touches 52-week low at $0.36 amid market challenges - Investing.com India
Balance Sheet Breakdown: Ensysce Biosciences Inc (ENSC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
ENSC stock touches 52-week low at $0.36 amid market challenges - Investing.com UK
Ensysce Biosciences announces $5M concurrent offering, shares fall - MSN
Ensysce Biosciences secures $5 million from stock sales - Investing.com
SEC Form 424B5 filed by Ensysce Biosciences Inc. - Quantisnow
ENSCEnsysce Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On? - Benzinga
3 Penny Stocks to Watch Now, 8/29/24 - TipRanks
Ensysce Biosciences secures $5 million from stock sales By Investing.com - Investing.com UK
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants - AccessWire
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants - StockTitan
Ensysce Biosciences Inc (ENSC) expanding its growth trajectory ahead - SETE News
Analyst Forecast For Ensysce Biosciences Inc (NASDAQ: ENSC) - Stocks Register
Market cap of Ensysce Biosciences Inc [ENSC] reaches 5.46M – now what? - The DBT News
Ensysce receives $14M grant for opioid trial By Investing.com - Investing.com Australia
Ensysce receives $14M grant for opioid trial - Investing.com
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
TSX Health Care Capped Index (TTHC) QuotePress Release - The Globe and Mail
A Closer Look at Ensysce Biosciences Inc (ENSC) Stock Gains - The InvestChronicle
TSX Cannabis Index (XCAN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Dow Futures Mini (YMZ21) Quote - The Globe and Mail
S&P 500 Consumer Discretionary [Sector] (SRCD) QuotePress Release - The Globe and Mail
Ensysce receives $14M grant for opioid trial By Investing.com - Investing.com UK
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):